Skip to main content

Rosetta Green Discloses License Negotiations with Seed Company

Premium

Rosetta Green announced this week that it is negotiating a deal under which “one of the world's largest seed companies” would license a “limited” number of microRNAs identified by Rosetta Green as potentially improving key traits within an undisclosed crop plant.

If an agreement is signed and the undisclosed seed company markets products incorporating the miRNA technology, Rosetta Green would be paid milestones and royalties.

Rosetta Green said that “if the negotiation between the parties will be successful, an agreement will be signed and executed in the near term,” but added that there is no guarantee this will occur.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.